Sagimet Biosciences Reports Progress in Acne and MASH Trials

Sagimet Biosciences, Inc. Class A ( (SGMT) ) has released its Q2 earnings. Here is a breakdown of the information Sagimet Biosciences, Inc. Class A presented to its investors.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting metabolic and fibrotic pathways, primarily through fatty acid synthase (FASN) inhibitors, for conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and acne.

In its latest earnings report, Sagimet Biosciences announced significant progress in its clinical trials, particularly highlighting the success of its FASN inhibitor, denifanstat, in a Phase 3 trial for acne conducted by its partner Ascletis in China. Additionally, the company has initiated a Phase 1 clinical trial in the U.S. for another FASN inhibitor, TVB-3567, aimed at treating acne.

Key financial metrics reveal that Sagimet ended the second quarter of 2025 with $135.5 million in cash and equivalents. The company reported increased research and development expenses, totaling $22.6 million for the first half of 2025, up from $11.6 million in the same period in 2024. General and administrative expenses also saw a rise, contributing to a net loss of $28.6 million for the first half of 2025, compared to $14.7 million the previous year.

Strategically, Sagimet is advancing its clinical programs with plans to initiate a Phase 1 trial for a combination therapy involving denifanstat and resmetirom in the latter half of 2025, with results expected in the first half of 2026. This development is part of their broader strategy to explore the therapeutic potential of FASN inhibition across various disease states.

Looking forward, Sagimet’s management remains optimistic about the potential of their FASN inhibitors to address unmet medical needs in conditions like MASH and acne, with ongoing trials and strategic partnerships expected to drive future growth and innovation.